Tetsuya Eto
YOU?
Author Swipe
View article: Age-related differences in donor selection priorities for allogeneic hematopoietic transplantation
Age-related differences in donor selection priorities for allogeneic hematopoietic transplantation Open
Patient age might influence donor selection priorities in allogeneic hematopoietic stem cell transplantation (allo-HCT), due to the differences in donor age, organ function, and resistance to graft-versus-host disease between younger and o…
View article: Adjusting Disease Risk Index for Regional Variations and Donor Selection: TRUMP cohort study
Adjusting Disease Risk Index for Regional Variations and Donor Selection: TRUMP cohort study Open
The Disease Risk Index (DRI) is a widely used prognostic tool following hematopoietic stem cell transplantation (HSCT), based on disease classification and status. However, the refined DRI (rDRI) does not fully account for regional variati…
View article: Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Adult T-Cell Leukemia/Lymphoma: A Nationwide Retrospective Study
Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Adult T-Cell Leukemia/Lymphoma: A Nationwide Retrospective Study Open
Adult T-cell leukemia/lymphoma (ATL) is a peripheral T-cell lymphoma with a dismal prognosis. Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only potentially curative treatment, its application in older…
View article: A comparative study of GVHD prophylaxis using low dose ATG versus PTCy for PBSCT based on two independent prospective cohorts
A comparative study of GVHD prophylaxis using low dose ATG versus PTCy for PBSCT based on two independent prospective cohorts Open
View article: The impact of the SARS-CoV-2 pandemic on umbilical cord blood transplantation in Japan: insights from an interrupted time series analysis
The impact of the SARS-CoV-2 pandemic on umbilical cord blood transplantation in Japan: insights from an interrupted time series analysis Open
View article: Engraftment outcome of patients with anti-HLA antibodies in HLA-mismatched peripheral blood stem cell transplantation
Engraftment outcome of patients with anti-HLA antibodies in HLA-mismatched peripheral blood stem cell transplantation Open
Anti-human leukocyte antigen (HLA) antibodies, particularly donor-specific HLA antibodies (DSA), negatively impact engraftment in hematopoietic cell transplantation. Past studies have proposed various interventions to reduce DSA, but these…
View article: HLA‐matched related peripheral blood stem cell and bone marrow transplantation with RIC regimens yield comparable outcomes for adult AML
HLA‐matched related peripheral blood stem cell and bone marrow transplantation with RIC regimens yield comparable outcomes for adult AML Open
Introduction Understanding differences in clinical outcomes between PBSCT and BMT is important, and this study compared outcomes of HLA‐matched related PBSCT and BMT using reduced‐intensity conditioning (RIC) in adult acute myeloid leukemi…
View article: A Case of Acute Myeloid Leukemia with an FMS-like Tyrosine Kinase 3-tyrosine Kinase Domain Mutation Developing Gilteritinib-induced Differentiation Syndrome
A Case of Acute Myeloid Leukemia with an FMS-like Tyrosine Kinase 3-tyrosine Kinase Domain Mutation Developing Gilteritinib-induced Differentiation Syndrome Open
FMS-like tyrosine kinase 3 (FLT3) mutations are observed in 30% of acute myeloid leukemia (AML) cases and indicate a poor prognosis. FLT3 inhibitors, such as gilteritinib, improve outcomes but may cause differentiation syndrome (DS) in app…
View article: Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post‐transplantation cyclophosphamide for adult T‐cell leukaemia/lymphoma
Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post‐transplantation cyclophosphamide for adult T‐cell leukaemia/lymphoma Open
Summary This study retrospectively compared outcomes of various allogeneic haematopoietic cell transplantation (allo‐HCT) platforms in patients with adult T‐cell leukaemia/lymphoma. Platforms included human leukocyte antigen (HLA)‐haploide…
View article: Augmented use of L-asparaginase markedly improves AYA ALL outcomes: FBMTG prospective MRD2014 study
Augmented use of L-asparaginase markedly improves AYA ALL outcomes: FBMTG prospective MRD2014 study Open
The enhanced utilization of native L-asparaginase (L-Asp) aims to improve treatment outcomes for adult patients with non-Philadelphia chromosome (Ph) acute lymphoblastic leukemia (ALL). In this measurable residual disease 2014 (MRD2014) st…
View article: Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i> Open
PURPOSE Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with AML harboring an internal tandem duplication mutation of FLT3 ( FLT3-ITD) AML. These patients are routinely treated with a FLT3 inhibitor after…
View article: Prognostic factors in haploidentical transplantation with post-transplant cyclophosphamide for acute myeloid leukemia
Prognostic factors in haploidentical transplantation with post-transplant cyclophosphamide for acute myeloid leukemia Open
The present study revealed significant prognostic factors in haplo-HCT with PTCy, and a scoring system based on these factors may be used to predict outcomes.
View article: Development of an umbilical cord blood transplantation–specific nonrelapse mortality risk assessment score
Development of an umbilical cord blood transplantation–specific nonrelapse mortality risk assessment score Open
Higher rate of nonrelapse mortality (NRM) remains yet to be resolved in umbilical cord blood transplantation (UCBT). Considering that UCBT has some unique features compared with allogeneic hematopoietic cell transplantation from other graf…
View article: Table of Contents
Table of Contents Open
View article: Prognostic impact of the conditioning intensity on outcomes after allogeneic transplantation for MDS with low blasts: A nationwide retrospective study by the adult MDS working group of the Japan Society for Transplantation and Cellular Therapy
Prognostic impact of the conditioning intensity on outcomes after allogeneic transplantation for MDS with low blasts: A nationwide retrospective study by the adult MDS working group of the Japan Society for Transplantation and Cellular Therapy Open
Poor prognostic factors, such as transfusion dependency and chromosomal risk, need to be considered in the indication of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients harboring myelodysplastic syndromes with l…
View article: Development and evaluation of a rapid one-step high sensitivity real-time quantitative PCR system for minor <i>BCR-ABL</i> (e1a2) test in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
Development and evaluation of a rapid one-step high sensitivity real-time quantitative PCR system for minor <i>BCR-ABL</i> (e1a2) test in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) Open
Objective Minimal residual disease assessment of BCR-ABL messenger ribonucleic acid levels is crucial in Philadelphia chromosome-positive acute lymphoblastic leukemia for prognosis and treatment planning. However, accurately quantifying mi…
View article: Hematopoietic stem cell transplantation from haploidentical offspring donors using post‐transplant cyclophosphamide versus human leukocyte antigen‐matched siblings in older patients with myelodysplastic syndrome
Hematopoietic stem cell transplantation from haploidentical offspring donors using post‐transplant cyclophosphamide versus human leukocyte antigen‐matched siblings in older patients with myelodysplastic syndrome Open
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for myelodysplastic syndrome (MDS) and has been increasingly performed in older patients, the majority of whom have MDS.1 Donors are important factors…
View article: Outcomes in human T-cell leukemia virus type I carriers after hematopoietic stem cell transplantation for diseases other than adult T cell leukemia/lymphoma: a Japanese national survey
Outcomes in human T-cell leukemia virus type I carriers after hematopoietic stem cell transplantation for diseases other than adult T cell leukemia/lymphoma: a Japanese national survey Open
View article: Posttransplant cyclophosphamide in HLA-matched and 1-2 allele mismatched peripheral blood stem cell transplantation
Posttransplant cyclophosphamide in HLA-matched and 1-2 allele mismatched peripheral blood stem cell transplantation Open
Posttransplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis has been increasingly used in HLA-haploidentical transplantation and recent studies also demonstrated the efficacy of PTCy in HLA-matched transplanta…
View article: Impact of different fludarabine doses in the fludarabine-based conditioning regimen for unrelated bone marrow transplantation
Impact of different fludarabine doses in the fludarabine-based conditioning regimen for unrelated bone marrow transplantation Open
To compare the effect of fludarabine (Flu) dose, the clinical outcomes of patients who received Flu and busulfan (FB; n = 1647) or melphalan (Flu with melphalan (FM); n = 1162) conditioning for unrelated bone marrow transplantation were re…
View article: Selection of Cord Blood Unit by CD34+ Cell and GM-CFU Numbers and Allele-Level HLA Matching in Single Cord Blood Transplantation
Selection of Cord Blood Unit by CD34+ Cell and GM-CFU Numbers and Allele-Level HLA Matching in Single Cord Blood Transplantation Open
In Japan, only single-unit cord blood transplantations (CBTs) are typically performed, and their number has increased over the last 23 years, with ongoing improvement in results. In most cases, CBTs with multiple HLA mismatches are used, o…
View article: P1261: NEGATIVE IMPACT OF HLA-B LEADER MISMATCH ON OUTCOMES OF HCT WITH PTCY FOR LYMPHOID MALIGNANCIES: A RETROSPECTIVE ANALYSIS FROM THE JAPANESE SOCIETY FOR TRANSPLANTATION AND CELLULAR THERAPY
P1261: NEGATIVE IMPACT OF HLA-B LEADER MISMATCH ON OUTCOMES OF HCT WITH PTCY FOR LYMPHOID MALIGNANCIES: A RETROSPECTIVE ANALYSIS FROM THE JAPANESE SOCIETY FOR TRANSPLANTATION AND CELLULAR THERAPY Open
Topic: 22. Stem cell transplantation - Clinical Background: HLA-B leader encodes methionine (M) or threonine (T) at position 2 and gives rise to TT, MT, or MM genotype. The HLA-B leader mismatch is a risk factor for worse outcomes in HLA 1…
View article: Impact of <scp>MRD</scp> on clinical outcomes of unrelated hematopoietic stem cell transplantation in patients with Ph<sup>+</sup><scp>ALL</scp>: A retrospective nationwide study
Impact of <span>MRD</span> on clinical outcomes of unrelated hematopoietic stem cell transplantation in patients with Ph<sup>+</sup><span>ALL</span>: A retrospective nationwide study Open
Measurable residual disease (MRD) status before transplantation has been shown to be a strong prognostic factor in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph + ALL). However, the outcomes of unrelated h…
View article: Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma
Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma Open
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) are curative treatment modalities for diffuse large B-cell lymphoma (DLBCL) because of the intrinsic graft-versus-lymphoma effect. However, limited information is available reg…
View article: Prognostic impact of HLA supertype mismatch on outcomes after single-unit cord blood transplantation
Prognostic impact of HLA supertype mismatch on outcomes after single-unit cord blood transplantation Open
Backgrounds: The “human leukocyte antigen (HLA) supertype” is a functional classification of HLA alleles, which was defined by structural features and peptide specificities, and has been reportedly associated with the clinical outcomes of …
View article: Data from Differential Effect of Graft-versus-Host Disease on Survival in Acute Leukemia according to Donor Type
Data from Differential Effect of Graft-versus-Host Disease on Survival in Acute Leukemia according to Donor Type Open
Purpose:The anti-leukemic activity of allogeneic hematopoietic cell transplantation (HCT) depends on both the intensity of conditioning regimen and the strength of the graft-versus-leukemia (GVL) effect. However, it is unclear whether the …
View article: Data from Differential Effect of Graft-versus-Host Disease on Survival in Acute Leukemia according to Donor Type
Data from Differential Effect of Graft-versus-Host Disease on Survival in Acute Leukemia according to Donor Type Open
Purpose:The anti-leukemic activity of allogeneic hematopoietic cell transplantation (HCT) depends on both the intensity of conditioning regimen and the strength of the graft-versus-leukemia (GVL) effect. However, it is unclear whether the …
View article: Supplementary Data from Differential Effect of Graft-versus-Host Disease on Survival in Acute Leukemia according to Donor Type
Supplementary Data from Differential Effect of Graft-versus-Host Disease on Survival in Acute Leukemia according to Donor Type Open
Supplementary Data
View article: Supplementary Data from Differential Effect of Graft-versus-Host Disease on Survival in Acute Leukemia according to Donor Type
Supplementary Data from Differential Effect of Graft-versus-Host Disease on Survival in Acute Leukemia according to Donor Type Open
Supplementary Data
View article: Progress in survival following three decades of allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: A real‐world registry study in Japan
Progress in survival following three decades of allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: A real‐world registry study in Japan Open
Allogeneic hematopoietic cell transplantation (HCT) can eradicate myelodysplastic syndrome (MDS) clones through high-dose chemoradiotherapy and the graft-versus-tumor effect,1 and it remains the only potentially curative treatment modality…